MHRA counterfeit weight loss pens haul in Birmingham shows illicit packing at scale

UK regulators have seized more than 12,000 fake weight loss pens from an industrial unit in Birmingham, in what they valued at about £2 million. The MHRA counterfeit weight loss pens haul on October 14, 2026 held products labelled as retatrutide and tirzepatide, plus packaging for around 30,000 more units. It is the fourth such operation in a year, and it shows illicit supply copying the packing stage of legitimate production.

What officers found in Birmingham

The raid was carried out on the night of October 14 by the Medicines and Healthcare products Regulatory Agency together with West Midlands Police, the agency said in a statement the next day. Officers recovered more than 12,000 pens presented as retatrutide or tirzepatide and packaging for about 30,000 further products. The MHRA put the value of the seized goods at around £2 million and described the site as a dirty warehouse on an industrial estate. It did not say whether anyone was arrested, who rented the unit, or whether the pens were filled there or arrived already assembled. No test results on the contents of the MHRA counterfeit weight loss pens have been published, so what they actually hold is unknown.

Tim Duffield, head of intelligence at the agency's Criminal Enforcement Unit, said the products "have not been assessed for safety, quality or effectiveness, and there is no guarantee of what they contain or whether they have been contaminated with harmful substances." He tied the case to "organised criminal gangs" running an illegal trade in unauthorised medicines. The MHRA statement on the seizure also stresses the legal position of one of the two products named on the pens. Retatrutide is an investigational triple agonist from Eli Lilly that has not been authorised in the UK, so any supply outside legitimate clinical trials is illegal. Tirzepatide, by contrast, is an authorised medicine, which makes copies of it harder for buyers to tell apart from the real product.

A string of raids since October 2025

The Birmingham case is the latest in a series that the agency listed in its statement. In October 2025, it dismantled what it called the first illicit weight loss medicine production facility found in the UK, seizing 5,000 retatrutide and tirzepatide pens, thousands of empty pens and raw chemical ingredients. In February 2026, about 2,000 doses awaiting dispatch were taken along with manufacturing equipment, suspected ingredients, packaging and vehicles. In May 2026, two people were arrested after a raid on a country estate thought to be used to make, assemble and distribute unlicensed products, with around 12,000 doses recovered. Each case points to a supply chain that stretches from bulk powder to finished, packed pens.

Each case points to a supply chain that stretches from bulk powder to finished, packed pens.

The pattern matters for anyone tracking where peptide medicines are really made. Legitimate tirzepatide comes from controlled plants, including Eli Lilly's sites for the active ingredient such as the planned expansion at Lebanon in Indiana, and from licensed fill and finish lines. The illegal chain copies the same stages in miniature, with bulk powder, empty pen bodies, labels and cartons gathered in rented units. Manufacturing Chemist noted that the Birmingham haul and the 2025 facility both held components and packaging, which suggests the networks source parts and ingredients rather than only reselling finished fakes. That is a trade problem as much as a policing one.

Where the illicit ingredient comes from

The MHRA did not say where the active ingredient in any of the seized pens was made. That gap is common in these cases. In other markets, regulators have traced ingredient for unlicensed products to overseas bulk suppliers selling outside the regulated chain, while licensed medicines must name an approved ingredient source in their marketing file. Regulators have tightened checks on such flows elsewhere. In the United States, the FDA shut out two Chinese plants that made GLP 1 ingredients for compounders after inspectors found serious failures, and it keeps a list of approved ingredient sources for semaglutide and tirzepatide imports.

The wider picture is not confined to the UK. Manufacturing Chemist pointed to warnings from the World Health Organization about falsified medicines, including semaglutide reported in all regions since 2022, to European Medicines Agency alerts about illegal products sold as approved GLP 1 medicines, and to Europol's Operation SHIELD VI, which ran from April to November 2025 and seized €33 million of counterfeit medicines and illegal supplements across 30 countries. For legitimate makers, each wave of fakes raises the cost of anti counterfeit features on pens and cartons. For regulators, it means following packaging and powder shipments as closely as finished pens, since the parts arrive before the product is assembled.

What remains unknown after the raid

Several basic facts are missing from the public record. The MHRA counterfeit weight loss pens case has no announced arrests, no named company and no laboratory analysis of what the pens contained. It is not clear whether the Birmingham unit filled pens itself, relabelled products made elsewhere or only stored and shipped them. The source of the powder, the pen bodies and the printed packaging has not been disclosed. The agency also did not say how long the site had been running, how many pens may already have been sold, or whether the case links to the earlier raids. Answers to those questions would show how much of the illegal chain sits inside the UK.

For readers following supply, two practical points stand. Retatrutide has no marketing authorisation in the UK, so any pen sold under that name outside a trial is unlicensed by definition. And the regulator's advice is that GLP 1 medicines should come only from a registered pharmacy with a valid prescription. Rules and enforcement on these flows sit in our trade coverage, where tariffs, import alerts and supplier laws are tracked. Until the investigation reports, the October seizure is best read as evidence of an illicit supply chain with scale and organisation rather than as a single rogue operation. The next MHRA update, or a court case, should show how far that chain reaches.

Conclusion

The MHRA counterfeit weight loss pens seizure in Birmingham removed more than 12,000 fake retatrutide and tirzepatide pens and packaging for about 30,000 more, valued at about £2 million. It follows raids in October 2025, February 2026 and May 2026. The origin of the ingredient, who assembled the pens and whether charges follow are still unknown.